Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Ziftomenib + imatinib in Gastrointestinal stromal tumors. The expected timing is based on the latest available company guidance and may change.
8/8/24- FDA cleared IND. 4/28/25- First patient dosed in Ph1. 11/04/25:- PR No update. 01/11/26:- Ongoing Phase 1a ziftomenib plus imatinib GIST trial highlighted as key 2026 non-AML expansion. 03/05/26:- Plan to advance KOMET-015 enrollment for ziftomenib plus imatinib in gastrointestinal stromal tumors. 05/12/26:- KOMET-015 Phase 1 ziftomenib plus imatinib GIST enrollment continuing; no new timing disclosed. 08/12/26:- KOMET-015 enrollment continues; no new timing disclosed.
Verification
Confirm timing and program details against the company announcement or filing.